相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Identification of WEE1 as a potential molecular target in cancer cells by RNAi screening of the human tyrosine kinome
Lyndsay M. Murrow et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
RNAi Screening for the Discovery of Novel Modulators of Human Disease
Attila A. Seyhan et al.
CURRENT PHARMACEUTICAL BIOTECHNOLOGY (2010)
Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor: Results of a Phase II Trial in Patients With Advanced Non-Small-Cell Lung Cancer
Lecia V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer
Harold J. Burstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941
Teemu T. Junttila et al.
CANCER CELL (2009)
Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells
Claudia Scholl et al.
CELL (2009)
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
Ji Luo et al.
CELL (2009)
A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors
Kwok-K. Wong et al.
CLINICAL CANCER RESEARCH (2009)
Safety, Pharmacokinetics, and Antitumor Activity of AMG 386, a Selective Angiopoietin Inhibitor, in Adult Patients With Advanced Solid Tumors
Roy S. Herbst et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer
David O. Azorsa et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2009)
Synergistic drug combinations tend to improve therapeutically relevant selectivity
Joseph Lehar et al.
NATURE BIOTECHNOLOGY (2009)
Integrated Functional, Gene Expression and Genomic Analysis for the Identification of Cancer Targets
Elizabeth Iorns et al.
PLOS ONE (2009)
A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor
Nicholas C. Turner et al.
EMBO JOURNAL (2008)
What is triple-negative breast cancer?
William J. Irvin et al.
EUROPEAN JOURNAL OF CANCER (2008)
How basal are triple-negative breast cancers?
Francois Bertucci et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Cancer - Deconstructing oncogenesis
Ji Luo et al.
NATURE (2008)
Combination chemical genetics
Joseph Lehar et al.
NATURE CHEMICAL BIOLOGY (2008)
Cancer proliferation gene discovery through functional Genomics
Michael R. Schlabach et al.
SCIENCE (2008)
Profiling essential genes in human mammary cells by multiplex RNAi screening
Jose M. Silva et al.
SCIENCE (2008)
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer
Katrien Berns et al.
CANCER CELL (2007)
A chemical screen identifies anisomycin as an anoikis sensitizer that functions by decreasing FLIP protein synthesis
Imtiaz A. Mawji et al.
CANCER RESEARCH (2007)
The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272
Y. Minami et al.
ONCOGENE (2007)
Utilizing RNA interference to enhance cancer drug discovery
Elizabeth Iorns et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs
Charles Swanton et al.
CANCER CELL (2007)
Synthetic lethal screen identification of chemosensitizer loci in cancer cells
Angelique W. Whitehurst et al.
NATURE (2007)
Chemical combination effects predict connectivity in biological systems
Joseph Lehar et al.
MOLECULAR SYSTEMS BIOLOGY (2007)
Role of the progesterone receptor for paclitaxel resistance in primary breast cancer
M. Schmidt et al.
BRITISH JOURNAL OF CANCER (2007)
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
Ian Smith et al.
LANCET (2007)
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
Richard M. Neve et al.
CANCER CELL (2006)
Probing the human kinome for kinases involved in pancreatic cancer cell survival and gemcitabine resistance
Valentin Giroux et al.
FASEB JOURNAL (2006)
The connectivity map: Using gene-expression signatures to connect small molecules, genes, and disease
Justin Lamb et al.
SCIENCE (2006)
shRNA libraries and their use in cancer genetics
Rene Bernards et al.
NATURE METHODS (2006)
A loss-of-function RNA interference screen for molecular targets in cancer
VN Ngo et al.
NATURE (2006)
Gene expression profiling of breast cell lines identifies potential new basal markers
E Charafe-Jauffret et al.
ONCOGENE (2006)
An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors
TR Brummelkamp et al.
NATURE CHEMICAL BIOLOGY (2006)
PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer
T Fujita et al.
BRITISH JOURNAL OF CANCER (2006)
Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies
Ting-Chao Chou
PHARMACOLOGICAL REVIEWS (2006)
Molecular classification and molecular forecasting of breast cancer: Ready for clinical application?
JD Brenton et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Ribo-gnome: The big world of small RNAs
PD Zamore et al.
SCIENCE (2005)
Activity of suberoylanilide hydroxamic acid against human breast cancer cells with amplification of Her-2
P Bali et al.
CLINICAL CANCER RESEARCH (2005)
Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance
JP MacKeigan et al.
NATURE CELL BIOLOGY (2005)
Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity
HR Tsou et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Mechanisms of gene silencing by double-stranded RNA
G Meister et al.
NATURE (2004)
Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase
SK Rabindran et al.
CANCER RESEARCH (2004)
Use of RNA interference libraries to investigate oncogenic signalling in mammalian cells
J Downward
ONCOGENE (2004)
Killing the messenger: Short RNAs that silence gene expression
DM Dykxhoorn et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2003)
Normalization of cDNA microarray data
GK Smyth et al.
METHODS (2003)
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
T Sorlie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Establishment of a chemical synthetic lethality screen in cultured human cells
A Simons et al.
GENOME RESEARCH (2001)
分享论文
